Viral Vector– tag –
-
Sartorius Revolutionizes Protein Production with Rational CHO Host Cell Engineering: Maximizing Intrinsic Expression Capacity
BioProcess International (Sartorius) Germany Overview Sartorius presented a webcast on rational CHO (Chinese Hamster Ovary) host cell engineering, aiming to significantly boost protein production. Diverging from traditional optimization ... -
Matica Biotechnology and Cirsium Biosciences Partner to Accelerate Flexible AAV Manufacturing via Matica Open Access Platform, Integrating Plant-Based Technology and Single-Use Innovations
BioSpace USA Overview Matica Biotechnology and Cirsium Biosciences announced the adoption of Matica's Open Access Platform to enhance flexibility, transparency, and scalability in Adeno-Associated Virus (AAV) development and manufacturin... -
ASCO 2026 Highlights CAR-T Cell Therapy Evolution in Multiple Myeloma: Focus on Rapid Manufacturing, Dual-Targeting, and Lentiviral Approaches
YouTube (OncUpdates) USA Overview A YouTube video featuring Dr. Hamza Hashmi discussed the latest advancements in CAR-T therapy for multiple myeloma at ASCO 2026. CAR-T therapy has evolved from a last-resort treatment to a viable option ... -
CDMO Signal Ranks Lentiviral Vector (LVV) CDMOs: GMP Standards and Robust Assays Key for Selection
CDMO Signal USA Overview CDMO Signal published its ranking of Lentiviral Vector (LVV) CDMOs based on Signal Score. LVVs are critical in ex vivo gene therapies for engineering CAR-T cells and modifying hematopoietic stem cells, necessitat... -
Qihan Biotech Receives FDA RMAT and Breakthrough Therapy Designations for Universal Dual-Target CAR-T Therapy, Supported by PackGene Biotech’s CDMO Expertise
PackGene Biotech China Overview Qihan Biotech announced that its universal dual-target CAR-T therapy received both Regenerative Medicine Advanced Therapy (RMAT) and Breakthrough Therapy designations from the U.S. FDA. PackGene Biotech, a... -
Lonza Presents Optimization Strategies to Address Purity and Potency Challenges in In Vivo Lentiviral Vector Development for Cell and Gene Therapies
Biocompare Switzerland Overview Lonza outlined optimization strategies for lentiviral vector (LVV) development for in vivo delivery of cell and gene therapies. Key challenges in LVV development include achieving purity, complexity of val... -
CCRM, OmniaBio, and Avectas Partner to Enhance Cell Therapy Manufacturing with Automated Platform Evaluation
BioSpace Canada Overview CCRM and its CDMO subsidiary, OmniaBio Inc., have partnered with Avectas Limited to evaluate an automated, integrated, and scalable cell therapy manufacturing platform. This collaboration aims to explore how Avec... -
VIVEbiotech Reaches 15 In Vivo Lentiviral Vector Programs, Fortifying Gene Therapy Manufacturing Leadership
BioPharma BoardRoom スペイン Overview VIVEbiotech has significantly advanced its position in gene therapy manufacturing by adding its 15th in vivo lentiviral vector (LVV) therapeutic program. This milestone underscores the company's robu... -
Frontiers Reports GMP-Compliant Scalable Manufacturing Platform Established for Allogeneic Type 1 Regulatory T Cells (TRX103)
Frontiers in Immunology Switzerland Overview A study published in Frontiers reports the establishment of a GMP-compliant, scalable manufacturing platform for TRX103, an allogeneic Type 1 regulatory T cell (Tr1 cell). While TRX103 has sho... -
Efficient Prime Editing In Vivo and In Vitro Demonstrated with Lipid Nanoparticles: High Efficacy, Low Off-Target Effects
PubMed International Overview Recent research reports the development of an optimized platform for prime editing using lipid nanoparticles (PE-LNP), demonstrating high gene editing efficiency in vivo. This LNP-based system offers a compe...
